Litcius/Paper detail

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

Evangelos Terpos, S. Vincent Rajkumar, Nelson Leung

2021JAMA Oncology21 citationsDOI

Abstract

This Viewpoint discusses the benefits of titer testing for anti–SARS-CoV-2 antibodies in patients with severe immunosuppression, including patients with multiple myeloma, following COVID-19 vaccination.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Multiple myeloma2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationVirologyAntibodyImmunologyNeutralizing antibodyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination | Litcius